Previous 10 | Next 10 |
home / stock / slncf / slncf news
2023-11-17 07:38:01 ET More on Virpax Pharmaceuticals Seeking Alpha’s Quant Rating on Virpax Pharmaceuticals Historical earnings data for Virpax Pharmaceuticals Financial information for Virpax Pharmaceuticals For further details see: Virpax Pharma...
SLN124 phase 1/2 study in polycythemia vera progressing well – data expected in mid-2024 Zerlasiran multiple dose study in patients with high Lp(a) and stable ASCVD showed significant and durable reductions in Lp(a) of up to 99% Fully enrolled zerlasiran phase 2 study in pa...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, Sile...
Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced an...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will partic...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results fo...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will p...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results fo...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...